Dose-seeking and Efficacy Study of Pembrolizumab Plus Vemurafenib and Cobimetinib for Therapy of Advanced Melanoma
Phase of Trial: Phase I
Latest Information Update: 13 Aug 2018
At a glance
- Drugs Pembrolizumab (Primary) ; Vemurafenib (Primary) ; Cobimetinib
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 01 Aug 2018 Planned End Date changed from 1 Oct 2018 to 1 Oct 2019.
- 01 Aug 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2019.
- 10 Apr 2018 Cobimetinib drug added to the study.